Previous studies in 2009 have shown TET2 mutation to be a favorable independent prognostic factor in myelodysplastic syndrome (MDS), and TET2 mutations were associated with poor outcomes in CMML patients [10]. The gene discussed is TET2; the disease is chronic myelomonocytic leukemia.